Protalix BioTherapeutics, Inc. (NYSE:PLX) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET
Company Participants
Mike Moyer – Investor Relations, LifeSci Advisors
Dror Bashan – President and Chief Executive Officer
Eyal Rubin – Senior Vice President and Chief Financial Officer
Conference Call Participants
John Vandermosten – Zacks Investment Research
Daniel Smith – H.C. Wainwright & Co., LLC
Robert Sassoon – Water Tower Research
Operator
Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2024 Financial and Business Results Conference Call. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Mike Moyer of LifeSci Advisors for Protalix. Thank you. You may begin.
Mike Moyer
Thank you, operator. And welcome to the Protalix BioTherapeutics third quarter 2024 financial results and business update conference call. With me today are Dror Bashan, President and CEO of Protalix, and Eyal Rubin, Senior Vice President and Chief Financial Officer. A press release announcing the financial results and business and clinical updates was issued this morning and is available now on the Protalix website.
Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protalix’s filings with the US Securities and Exchange Commission.
I’ll now turn the call over to Mr. Bashan. Dror?
Dror Bashan
Thank you, Mike. And thank you, everyone, for joining our third quarter 2024 financial results and business update call.
I will begin by reviewing our recent accomplishments before handing the
